Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 8/20 | 0.49 |
| ▸ | YAP1 | P46937 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.42 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20475182 | 0.95 | PRMT5 (0.48) | PRMT5YAP1MAOBGPR119NR4A1 | |
| SCHEMBL23040400 | 0.85 | PRMT5 (0.46) | PRMT5YAP1MAPT | |
| SCHEMBL25845320 | 0.83 | GPR119 (0.47) | KDM4EMEN1MAPTKMT2AGPR119 | |
| SCHEMBL25845399 | 0.82 | ESR2 (0.46) | KDM4EMAPTGPR119MAPK1 | |
| SCHEMBL20475154 | 0.81 | GPR119 (0.42) | PRMT5YAP1MAOBGPR119MAPK1 | |
| SCHEMBL1750649 | 0.78 | CHRM5 (0.48) | PRMT5YAP1MAPK1 | |
| SCHEMBL20475212 | 0.77 | GPR119 (0.47) | KDM4EMEN1MAPTKMT2AGPR119 | |
| SCHEMBL27114057 | 0.76 | YAP1 (0.56) | PRMT5YAP1MEN1KMT2AGPR119 | |
| SCHEMBL18550027 | 0.76 | PRMT5 (0.51) | PRMT5YAP1GPR119MAPK1 | |
| SCHEMBL8195218 | 0.76 | NAMPT (0.57) | PRMT5YAP1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303531-A1 | 5-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME | TREVENA, INC. | 2023-09-28 | — | — | US | disclosed |
| US-11702408-B2 | 5-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same | TREVENA, INC. (US) | 2023-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702408-B2 | 5-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same | OPRD1, OPRM1, OPRK1 | PRMT5 526/4885YAP1 1693/4885KDM4E 827/4885 |
| US-20230303531-A1 | 5-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME | OPRD1, OPRM1, OPRK1 | PRMT5 479/4885YAP1 1539/4885KDM4E 729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.